Crocetin Induces Cytotoxicity in Colon Cancer Cells Via p53-independent Mechanisms

Li, Caiyan; Huang, Wenfeng; Wang, Qun-Li; Wang, Fan; Cai, Enqi; Hu, Bing; Du, Jia-Cheng; Wang, Jing; Chen, Rong; Cai, Xiaoyu; Feng, Jing; Li, Hui

doi:10.7314/apjcp.2012.13.8.3757

Cited by 50 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition,the mice lacking the cry 1 and 2 genes lose periodicity in wheel-running behavior (Vander et al, 1999) as well as electrophysiological activity in the SCN cells under constant darkness (DD) (Bonnefont et al, 2003). In another sepatrae study, CRY1 has been previously shown to undergo aberrant DNA methylation events in Human Chronic Myeloid Leukemia (Huttmann et al, 2012;Li et al, 2012). Based on these results, we propose that inactivation of the cry1 and cry2 in glioma cells may result in deregulation of the cell cycles thus favoring the proliferation of glioma cells, as deregulated expression of the cry1 genes is common in gliomas.…”

Section: Discussionmentioning

confidence: 99%

Deregulated Expression of Cry1 and Cry2 in Human Gliomas

Luo¹,

Fan²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Growing evidence shows that deregulation of the circadian clock plays an important role in the development of malignant tumors, including gliomas. However, the molecular mechanisms of gene chnages controlling circadian rhythm in glioma cells have not been explored. Using real time polymerase chain reaction and immunohistochemistry techniques, we examined the expression of two important clock genes, cry1 and cry2, in 69 gliomas. In this study, out of 69 gliomas, 38 were cry1-positive, and 51 were cry2-positive. The expression levels of cry1 and cry2 in glioma cells were significantly different from the surrounding non-glioma cells (P<0.01). The difference in the expression rate of cry1 and cry 2 in high-grade (grade III and IV) and low-grade (grade 1 and II) gliomas was non-significant (P>0.05) but there was a difference in the intensity of immunoactivity for cry 2 between high-grade gliomas and low-grade gliomas (r=-0.384, P=0.021). In this study, we found that the expression of cry1 and cry2 in glioma cells was much lower than in the surrounding non-glioma cells. Therefore, we suggest that disturbances in cry1 and cry2 expression may result in the disruption of the control of normal circadian rhythm, thus benefiting the survival of glioma cells. Differential expression of circadian clock genes in glioma and non-glioma cells may provide a molecular basis for the chemotherapy of gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Deregulated Expression of Cry1 and Cry2 in Human Gliomas

Luo¹,

Fan²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, PI3K amplification/mutation, AKT overexpression, loss of PTEN and P53 function, and overexpression of S6K1 have all been associated with cancer development and are linked to the mTOR signaling pathway (Li et al, 2012;Xu et al, 2014;Zhang et al, 2014;Zhao et al, 2014). Although mutations of mTOR itself have not been reported, mutations in components of mTOR-related signaling pathways have frequently been described in various human malignancies.…”

Section: Discussionmentioning

confidence: 99%

Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

Xiao¹,

Chen²,

Qin³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Oridonin, an ent-kaurane diterpenoid compound isolated from the traditional Chinese herb Rabdosia rubescens, has shown various pharmacological and physiological effects such as anti-tumor, anti-bacterial, and anti-inflammatory properties. However, the effect of oridonin on human ovarian cancer cell lines has not been determined. In this study, we demonstrated that oridonin inhibited ovarian cancer cell proliferation, migration and invasion in a dose-dependent manner. Furthermore, we showed oridonin inhibited tumor growth of ovarian cancer cells (SKOV3) in vivo. We then assessed mechanisms and found that oridonin specifically abrogated the phosphorylation/activation of mTOR signaling. In summary, our results indicate that oridonin is a potential inhibitor of ovarian cancer by blocking the mTOR signaling pathway. Keywords

show abstract

“…They have an inhibitory effect on the intracellular nucleic acid and protein synthesis in malignant cells as well as on protein kinase C (PKC) and pro-oncogene in INNIH/3T3 cells (Giaccio et al, 2004), which is most likely due to their antioxidant activity. Crocetin has no function in colony forming of tumor cells, but it could inhibit DNA, RNA and protein synthesis of human malignant tumor cells in a dose dependent manner (Ashrafi et al, 2005), which may be related to p53-dependent mechanisms (Li et al, 2012). In addition, crocetin could reduce interaction between hitone H1and DNA in vitro, interfere gene transcription (Magesh et al, 2006).…”

Section: Discussionmentioning

confidence: 99%